Explore oncology’s recent research boom and where the industry is headed next.
Drugmakers and, largely, the FDA argue that the medicines now being reviewed are different than the chemotherapies and blunter interventions of the past. This is having consequences for how clinical trials are being run, and for how much money drugmakers are investing in cancer R&D.
Included in this Trendline
- Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda
- ‘The bar has risen’: China’s biotech gains push US companies to adapt
- Led by Enhertu, ADCs look set to supplant chemo in HER2-low breast cancer
Offered Free by: BioPharma Dive and EVERSANA
See All Resources from: BioPharma Dive and EVERSANA
